Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Has a diagnosis of Type 2 Diabetes Mellitus (T2DM)~* Has HbA1c of 7.5% to 12.0%, inclusive, at Visit 1 (Screening).~* Has fasting plasma glucose (FPG) concentration \<280 mg/dL (15.6 mmol/L) at Visit 1 (Screening)~* Treated with basal insulin glargine at a dose of ≥20 units/day once daily for at least 6 weeks prior to Screening, in combination with diet and exercise alone or in combination with:~  1. a stable dose of metformin (≥1500 mg/day) for at least 8 weeks prior to Visit 1~ 2. a stable dose of metformin (≥1500 mg/day) for at least 8 weeks prior to Visit 1 (Screening) and a stable dose of sulfonylurea for at least 8 weeks prior to the Screening visit~Exclusion criteria:~* Serum calcitonin concentration ≥40 pg/mL (≥40 ng/L) at Visit 1 (Screening)~* History of, or currently have, acute or chronic pancreatitis, or have triglyceride concentrations ≥500 mg/dL (≥5.65 mmol/L) at Visit 1~* Positive serological test for hepatitis B or hepatitis C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide (Type: EXPERIMENTAL): Exenatide 2 mg 1 time per week + titrated basal insulin glargine with or without metformin
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 2 mg 1 time per week + titrated basal insulin glargine with or without metformin

Based on this trial design, predict the completion outcome and termination type (if applicable).